Search
Search Results
-
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
Antiangiogenic agents, generally antibodies or tyrosine-kinase inhibitors that target the VEGF–VEGFR pathway, are currently among the few combination...
-
Antiangiogenic Therapy for Malignant Brain Tumors: Does It Still Matter?
Purpose of ReviewTo summarize the mechanisms of tumor angiogenesis and resistance to antiangiogenic therapy, and the influence on tumor...
-
Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: a real-world observation study
PurposeThis study was performed to investigate the efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small...
-
Comparison of antiangiogenic agents (ranibizumab, aflibercept, bevacizumab and ziv-aflibercept) in the therapeutic response to the exudative form of age-related macular degeneration according to the treat-and-extend protocol- true head-to-head study
PurposeTo evaluate the structural and functional changes in eyes with neovascular age related macular degeneration (nAMD) in a real-world setting,...
-
Revisiting prognostic factors in glioma with leptomeningeal metastases: a comprehensive analysis of clinical and molecular factors and treatment modalities
PurposeTo comprehensively investigate prognostic factors, including clinical and molecular factors and treatment modalities, in adult glioma patients...
-
Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer
In our phase Ib trial (ClinialTrials.gov Identifier: NCT03855358), benmelstobart (TQB2450), a novel humanized IgG1 antibody against PD-L1, plus...
-
Antiangiogenic role of natural flavonoids and their molecular mechanism: an update
BackgroundAngiogenesis is the development of new blood vessels from the existing vasculature, which is important in normal developmental processes....
-
Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis
BackgroundA high baseline hepatitis B virus (HBV) load has always been listed as an exclusion criterion for programmed cell death-1 (PD-1)...
-
Preeclampsia at delivery is associated with lower serum vitamin D and higher antiangiogenic factors: a case control study
BackgroundPreeclampsia is characterized by decreased trophoblastic angiogenesis leading to abnormal invasion of spiral arteries, shallow implantation...
-
Real-World Data Analysis of Second-Line Antiangiogenic Targeted Treatments Following Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies and First-Line FOLFOX for Patients with Metastatic Colorectal Cancer
IntroductionEvidence is lacking on second-line and later treatments for patients with RAS wild-type colorectal cancer (CRC) who receive first-line...
-
Mdm2-mediated neddylation of pVHL blocks the induction of antiangiogenic factors
Mutations in the tumor suppressor TP53 are rare in renal cell carcinomas. p53 is a key factor for inducing antiangiogenic genes and RCC are highly...
-
Current Data on the Age-Related Macular Degeneration Pathophysiology: Focus on Growth Factors and Neurotrophins
AbstractAge is a main risk factor for age-related macular degeneration (AMD), a complex multifactorial neurodegenerative retinal disease that is...
-
Leukocyte Telomere Length and Response to Antiangiogenic Therapy in Patients with Neovascular Age-Related Macular Degeneration
AbstractAge-related macular degeneration (AMD) is becoming the leading cause of vision loss in people over 60 yr of age. The neovascular form of AMD...
-
Targeting Angiogenic Factors for the Treatment of Medulloblastoma
Medulloblastoma (MB) is the most frequent pediatric brain tumor. Despite conventional therapy, MB patients have high mortality and morbidity rates...
-
Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review
BackgroundIntraocular inflammation is an uncommon but potentially vision-threatening adverse event related to anti-VEGF therapy. This is of...
-
Debridement using Piezosurgical Device and Incorporation of Autologous Platelet-Rich Fibrin in Management of Stage III Medication-Related Osteonecrosis of the Jaw — A Case study and Review of Literature
Medication-related osteonecrosis of the jaw (MRONJ) is a condition of persistent exposure of bone or an introral/extraoral fistula through which the...
-
Unravelling the potential of angiogenic factors for the early prediction of preeclampsia
Preeclampsia is a multisystem, multiorgan hypertensive disorder of pregnancy responsible for maternal and perinatal morbidity and mortality in low-...
-
Research progress of exosomes in the angiogenesis of digestive system tumour
Malignant tumours of the digestive system cover a wide range of diseases that affect the health of people to a large extent. Angiogenesis is...
-
New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer
PurposeTumor growth relies on the sufficient blood supply and continuously requires new blood vessels to maintain, which lead to vascular...
-
Albuminuria as a biomarker of severity in diabetic retinopathy and in the response to intravitreal treatment in diabetic macular edema
PurposeDiabetic macular edema (DME) presents a suboptimal response to antiangiogenic treatment in approximately 30% of patients. We analyzed the...
